Inclusion Criteria:  Informed consent as documented by signature Patients that are at least 18 years old Patients that have at least one and no more than two diabetic foot ulcers (DFU) of ≥ 0.5 cm2 and < 5 cm2 as assessed by the ruler method multiplying the greatest length and width of the ulcer after debridement to determine the surface area. The largest eligible ulcer will be defined as index ulcer and the corresponding extremity as index limb (in case of two equally sized ulcers the following rules will apply: If on different feet, the dominant side and if on same foot, the more peripheral one will be the index ulcer)  Patients that have non-critical LEAD, defined by a single non-invasive examination at screening:  Ankle brachial index (ABI) ≥ 0.5 and ≤ 0.9 AND absolute ankle pressure > 50 mmHg AND toe pressure > 30 mmHg OR ABI ≥ 1.4 AND incompressible ankle pressures AND toe brachial index (TBI) ≤ 0.7 AND absolute toe pressure > 30 mmHg Patients on medical treatment for glycemic control with diagnosis of diabetes mellitus that was assessed by criteria as recommended by the guideline. Patients with life expectancy > 12 months and without any disabilities due to end-stage cancer, heart failure, severe chronic obstructive pulmonary disease (COPD), or dementia  Exclusion Criteria:  Critical limb ischemia defined as ABI < 0.4 (or ankle pressure < 50 mmHg or toe pressure < 30 mmHg) No option to assess for toe pressure due to any reason at baseline Need for major amputation Severe infection at the index foot according to IDSA classification Patient refuses minor amputation despite strong recommendation due to severe infection, necrosis or osteomyelitis at screening assessment. Any revascularization procedure at the index leg within 6 months before randomization Positive urine or blood pregnancy test result, breast feeding or intention to become pregnant Non-compliance for any reason to procedures or study assessments (e.g. due to cognitive impairment or geographic distance) Drug or alcohol abuse Participation in another study with investigational drug within the 30 days preceding or during the present study Untreated known antiphospholipid antibody syndrome and polycythaemia vera Known significant bleeding risk, or known coagulation disorder (INR > 3.0 and platelet count < 30,000/mm3) without any option to correct within 7 days after randomization